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Cancer immunotherapy has experienced remarkable advances in recent years.
Striking clinical responses have been achieved for several types of solid cancers
(e.g. melanoma, non-small cell lung cancer, bladder cancer and mismatch
repair-deficient cancers) after treatment of patients with T-cell checkpoint
blockade therapies. These have been shown to be particularly effective in
the treatment of cancers with high mutation burden, which places tumour-
mutated antigens (neo-antigens) centre stage as targets of tumour immunity
and cancer immunotherapy. With current technologies, neo-antigens can be
identified in a short period of time, which may support the development
of complementary, personalized approaches that increase the number of
tumours amenable to immunotherapeutic intervention. In addition to review-
ing the state of the art in cancer immunotherapy, we discuss potential avenues
that can bring the immunotherapy revolution to a broader patient group
including cancers with low mutation burden.1. Introduction
The field of cancer immunotherapy has experienced alternating periods of success
and failure in the development of cancer therapies. In the late nineteenth century,
William Coley treated cancer patients by local injection with bacterial toxins,
which provoked anti-tumour immune responses in some patients [1]. In the
1960s, Thomas and Burnet postulated the cancer immune surveillance theory,
where the immune system would specifically eliminate malignant cells, most
probably through recognition of tumour-associated antigens [2,3]. This was
followed by the elucidation of the role of T cells in anti-tumour immune responses
which led to the clinical use of the T-cell growth factor interleukin-2 (IL-2).
In 1991, IL-2 was approved by the FDA for the treatment of metastatic renal
cell carcinoma and, in 1998, for metastatic melanoma. However, IL-2 treatments
produced high toxicity and yielded a relatively low response rate, underlining
the need to develop improved immunotherapeutic strategies [4,5].
The transition to targeted immunotherapy was made with the development of
the hybridoma technology, in 1975, which supported the production of mono-
clonal antibodies [6]. Rapidly, monoclonal antibody-based treatments were
set up and the first FDA approval was obtained for rituximab in 1997 for the treat-
ment of B-cell lymphomas. Rituximab is a genetically engineered monoclonal
antibody directed against the CD20 antigen which is ubiquitously expressed in
B cells and triggers cell death by antibody-dependent cell-mediated cytotoxicity,
complement activation and direct induction of apoptosis [7,8]. In the same
decade, chimaeric antigen receptor (CAR) T cells were developed to combine
the antigen-binding properties of antibodies with the cytolytic and self-renewal
capacity of T cells [9,10]. CAR T cells are genetically engineered to express an
extracellular antigen-recognition domain, such as antibody-derived, single-
chain variable fragments, coupled to T-cell activation endodomains. The most
significant clinical results have been achieved with CD19-targeting CAR T cells
in haematological malignancies [11,12].
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immune checkpoints (e.g. PD-1/PD-L1 and CTLA-4) have
been developed to promote the activation of T cells and sub-
sequent tumour control. This treatment strategy has been
shown to be particularly effective in tumours with high muta-
tion burden, putting tumour-mutated antigens (neo-antigens)
centre stage in cancer immunotherapy [13–19].blishing.org
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immunotherapy
Antigen processing and presentation enables the immune
system to monitor cellular processes and to act accordingly
upon expression of aberrant/foreign proteins. Human leuko-
cyte antigen (HLA) class I molecules present antigens at the
surface of most cells throughout the organism. Such antigens
can, theoretically, be derived from most cellular proteins as
these are processed by the (immuno) proteasome and broken
down to peptides [20]. Subsequently, transporter associated
with antigen processing (TAP) proteins mediate the intake of
these peptides to the endoplasmic reticulum, where they are
loaded onto HLA class I molecules with the aid of several
chaperones [21,22]. HLA class I/peptide complexes translocate
via the Golgi apparatus to the cell surface where they are
exposed to CD8þ T cells [23]. Nevertheless, an effective
anti-tumour immune response is thought to be initiated by
the taking up of tumour antigens by antigen-presenting
cells (APCs) which in turn present them, and provide co-
stimulatory signals, to both CD4þ and CD8þ T cells [24]. In
order to do so, APCs, particularly dendritic cells, process anti-
gens through an exogenous antigen processing pathway where
(tumour) cellular material is phagocytosed and converted into
HLA class I- and class II-binding peptides that are presented to
CD8þ (cross-presentation) and CD4þ T cells, respectively [25].
HLA class II expression is also known to occur in some tumour
types although its functional significance and how it can be
exploited from an immunotherapeutic point of view require
further investigation [26,27].
Antigens that are considered to evoke anti-tumour
immune responses and which are therefore suitable as
immunotherapeutic targets can be divided into three groups:
tumour-mutated antigens (or neo-antigens), tumour-associated
antigens and cancer-testis antigens [28]. Viral antigens consti-
tute another class of targetable antigens in the context of viral
oncogenesis but will not be discussed here. Tumour-associated
and cancer-testis antigens are both self-antigens that are differ-
entially expressed in tumour tissues and rarely expressed (or to
lower extent) in normal tissues. The stimulation of endogenous
T-cell responses against self-antigens can be challenging as
auto-reactive T cells are subjected to negative selection in the
thymus [29]. Nevertheless, it has been shown that central toler-
ance can be broken and that immune responses can be
generated against self-antigens, analogous to what is observed
in autoimmunity [30]. Positive clinical indications have been
described for several tumour-associated antigens (e.g. gp100,
MART-1) and cancer-testis antigens (e.g. MAGE-A3 and
NY-ESO-1) [31–34]. However, subsequent clinical trials were
not always able to confirm patient survival benefits and side-
effects were regularly observed due to expression of the
targeted antigens in healthy tissues [35–37].
Neo-antigens are by definition tumour-specific as they
arise from somatic mutations that are not present in healthytissue. Theoretically, they constitute ideal targets for immu-
notherapy because no off-target reactivity and central
tolerance of T cells are expected [38]. The accumulation of
somatic mutations is a hallmark of tumour progression, but
only a minority of mutations is under positive selection
and, therefore, recurrently observed in different patients.
Hence, individual tumour mutation profiles are dominated
by the so-called passenger mutations which are highly vari-
able between cancers and patients [39]. The development of
next-generation sequencing (NGS) technologies has made it
possible to screen entire (coding) genomes for the detection
of potential neo-antigens in a clinically applicable time-
frame. In silico tools aiming at identifying neo-antigens
more likely to constitute good immunotherapy targets are
also under constant development [40–44].
The requirement of a personalized approach to target
neo-antigens can be a time-consuming and onerous procedure.
While this limitation could be circumvented by the targeting
of recurrent mutations at driver genes such as BRAF and
KRAS, accumulated evidence suggests that such mutations
are seldom immunogenic [45,46]. In fact, this might be
expected, as it would be unlikely that immunogenic mutations
would be so often favoured by clonal selection during tumour
progression. Another aspect complicating the targeting of
neo-antigens relates to intra-tumour heterogeneity. The
identification of neo-antigens requires that the tumour is
sampled and further processed for nucleic acid isolation and
sequencing. Several reports have identified sampling issues
as a major limitation for a comprehensive characterization of
somatic alterations in tumours [47,48]. On the other hand,
cancer therapies, including immunotherapies, will probably
be the most successful when targeting clonal alterations pre-
sent in any part of a tumour mass [13]. Another caveat that
must be considered is that neo-antigens, particularly the ones
derived from point mutations, have very similar sequences to
their wild-type counterpart. If amino acid substitutions at
anchor residues do not affect the binding affinity to HLA mol-
ecules or if substitutions at core residues do not significantly
alter the molecular properties of a peptide, the likelihood that
high avidity TCRs are present in an autologous T-cell repertoire
may be low. This supports a fundamental role for frameshift
mutations as these have the potential to generate highly immu-
nogenic peptides [49]. However, frameshifts are notoriously
difficult to detect, particularly in NGS data, and the capacity
to identify them varies greatly between research groups.3. The state of the art in cancer
immunotherapy
T cells are key players in anti-tumour immunity and, therefore,
the bulk of cancer immunotherapy research has focused on
inducing T-cell-mediated anti-tumour responses. The current
breakthrough in cancer immunotherapy results from the
identification and subsequent targeting of checkpoint mechan-
isms in T cells with antibodies against CTLA-4, PD-1 and
PD-L1 [50–53]. CTLA-4 and PD-1 are co-inhibitory receptors
found on the cell surface of T cells. Upon binding to their cor-
responding ligands (CD80/86 and PD-L1/-L2, respectively), T
cells become anergic: a physiological mechanism of peripheral
tolerance or halting of inflammatory responses [54]. In the con-
text of the tumour microenvironment, the aberrant expression




3together with chronic exposure to tumour antigens, can lead to
the undesirable suppression of T-cell activity [55]. The blocking
of such mechanisms can therefore unleash a renovated anti-
tumour immune response. Moreover, checkpoint blockers
were found to broaden the target of cytotoxic T-cell responses
in cancer patients [56,57].
Treatment with checkpoint blocking antibodies has been
approved for a number of cancers including melanoma,
urothelial bladder cancer, head and neck squamous cell
carcinoma, non-small cell lung cancer and classical Hodgkin
lymphoma, while positive indications has been found for
many other malignancies [50,58–62]. Immune checkpoint
blockade has been shown to be most effective in tumours
with high mutation burden that arises either from chronic
exposure to DNA-damaging agents (e.g. smoking and ultra-
violet radiation) or as a consequence of intrinsic DNA
repair defects [16,17,63]. Accordingly, clinical responses have
also been correlated with the mutation burden of tumours
derived from the same organ [16,17,62]. Notably, pembrolizu-
mab, an anti-PD-1 antibody, constitutes the FDA’s first tissue/
site-agnostic, molecular-guided approval as it is indicated for
advanced mismatch repair-deficient cancers. These findings
support the central role of neo-antigens in the therapeutic
responses to immune checkpoint blockers. Nevertheless, the
majority of patients with the so-called hypermutated tumours
do not respond to checkpoint blockade and the ability to pre-
dict responses by discovering additional biomarkers is a
major focus of research in the field [64]. In order for CD8þ T
cells to fulfil their cytotoxic activity, they must infiltrate
tumour tissues and subsequently recognize cancer antigens
loaded on HLA class I molecules. Therefore, defects in the
antigen processing and presentation machinery are often
observed as immunoediting phenotypes in tumour cells
[65–69]. Additionally, tumour cells can escape cytokine-
mediated immune responses by mutating components of the
IFN-g pathway. Metastatic melanoma patients that did not
respond to CTLA-4 treatment were found to have tumours
with genetic defects in IFNGR1/2, IRF1 and JAK2 [70]. Similarly,
melanoma and MMR-deficient colorectal cancer patients were
found to be resistant to anti-PD-1 treatment due to inactivating
mutations in JAK1/2 [71,72]. Neo-antigen availability can also
change in a tumour, due to clonal selection by immunoediting,
enforced by neo-antigen-specific T cells [73,74].
Spontaneous, neo-antigen-driven, anti-tumour responses
arise in many cancer patients, as demonstrated by the isolation
of neo-antigen-reactive tumour-infiltrating lymphocytes (TIL)
[75]. Furthermore, the presence of TIL, particularly with a type
1 inflammatory profile (i.e. IFNg/IL-2-driven immune
responses), is generally associated with an improved prognosis
in cancer patients [76,77]. One approach to boost an autologous
lymphocyte-mediated anti-tumour response is through adop-
tive T-cell transfer (ACT), which relies on the ex vivo expansion
of tumour-reactive T cells and their reinfusion back in the patient
[78]. The infusion product can consist of TIL or peripheral blood-
derived tumour-specific T cells that are expanded in the pres-
ence of tumour cells or tumour antigens [79,80]. ACT-based
treatments have produced some encouraging results, particu-
larly for metastatic melanoma patients [73,80–83]. Verdegaal
et al. reported on the successful treatment of a metastatic mela-
noma patient with CD4þ and CD8þ tumour-specific T cells
[73,80]. In a fascinating example, the potency of neo-antigen-
specific ACT is illustrated by the treatment of a metastatic
cholangiocarcinoma patient, treated with a neo-antigen-reactiveCD4þ T-cell product derived from TIL, resulting in stable
disease [82]. These findings underscore the relevance that ACT
might have for some patients, but similar to for checkpoint
blockade, there is a need to discover biomarkers that indicate
a priori which patients may benefit from it.
Today, many ongoing clinical trials are investigating the
clinical effect of combining different immunotherapies. The
use of anti-CTLA-4 in addition to anti-PD-1 antibodies resulted
in increased overall survival rates in previously untreated mel-
anoma patients [84,85]. Furthermore, other immune regulators,
such as LAG-3, TIM-3, ICOS or NKG2D are promising
new therapeutic targets [86–90]. Additional research will be
important to address resistance to first-generation immune
checkpoint blockers as, for instance, LAG-3 and TIM-3 upregu-
lation is observed following anti-PD-1 treatment [86]. Likewise,
CD137 co-stimulation is studied for its synergistic effects with
ACT [91,92]. Finally, checkpoint blockade therapies may also
be used in combination with standard chemo- and radio-
therapy interventions which are known to enhance tumour
immunogenicity [93,94].
Other avenues like therapeutic vaccination with synthe-
tic peptides corresponding to neo-antigens are being
explored. This strategy aims to prime autologous T cells
from cancer patients against tumour-specific antigens to
unleash anti-tumour immune responses. In addition to
providing neo-antigens as immunotherapy products, several
co-stimulatory factors are needed to induce an effective anti-
tumour T-cell response [95], including provision of danger
signals by adjuvants and/or homing of cellular-based vaccines
[96–98]. Encouraging clinical responses were obtained with
neo-antigen-based peptides plus polyICLC vaccinations
in previously untreated metastatic melanoma patients [99].
This intervention was shown to induce CD4þ and CD8þ anti-
tumour T-cell responses against several epitopes. Four out of
six patients had no recurrence after 25 months; two patients
with tumour recurrence received subsequent anti-PD1 therapy
leading to complete tumour regression [99]. In another phase I
study, stage III melanoma patients pre-treated with ipilimu-
mab and by surgical resection received a vaccine consisting
of autologous dendritic cells presenting neo-antigens that
were determined by sequencing [100]. Both vaccination
strategies induced tumour-directed immune responses with
concomitant broadening of the targeted antigen repertoire
without inducing side-effects [99,100]. Nevertheless, to date,
the number of vaccination studies involving neo-antigens
that reported positive clinical outcomes is limited. This might
be explained by the fact that the bulk of this research, in pre-
vious decades, has focused on targeting oncogenes and
tumour suppressors (e.g. TP53) with recurrent mutations
[101]. Therefore, these studies did not consider the largest
source of neo-antigens in tumour—passenger mutations.
The requirement that neo-antigens are presented in com-
plex with HLA class I hinders the widespread application of
neo-antigen-targeted therapies in the form of peptide vacci-
nation or ACT. Therefore, CAR T cells were designed to
enable the targeting of any cell surface molecule, in an HLA
non-restricted fashion [9]. This strategy has been particularly
successful for treating haematological malignancies, because
highly tissue/cell-restricted antigens are present on their
easily accessible cells of origin [10–12]. In 2010, the first suc-
cessful CAR T-cell therapy was reported in a lymphoma
patient who was pre-treated with chemotherapy [10]. The infu-




4retroviruses encoding the variable region of the anti-CD19,
B-cell antigen, which was joined to part of the co-stimulatory
CD28 molecule and CD3z signalling domain for T-cell
activation. Investigations in larger cohorts showed clinical
responses [102,103], but severe side-effects arose, including
treatment-related deaths [104–106]. These side-effects derive
from high cytokine concentrations (cytokine storm), produced
by the infused engineered T cells that become hyper-activated
as a result of high affinity of their receptor to the target
molecules. Recently, two second generation CAR therapies
targeting CD19 have been approved by the FDA for treatment
of patients with relapsed/refractory diffuse large B-cell
lymphoma and relapsed/refractory B-cell precursor acute
lymphoblastic leukaemia [107,108]. In search for optimal effec-
tivity and specificity, third generation CARs are currently
being developed, which contain two co-stimulatory domains
[109–112]. Furthermore, investigations are ongoing to improve
the treatment of haematological diseases while limiting the
severity of side-effects, as well as investigations on the clinical
efficacy of genetically engineered T cells in solid tumours
[109,113,114]. The targeting of the latter has proved to be
particularly challenging and complicating factors include the
identification of specific, targetable antigens and the homing
of CAR T cells to the tumour tissues where in turn they are
exposed to a complex tumour microenvironment [115]. On
the other hand, CAR T cells are a very attractive tool to treat
cancers arising in non-vital organs where specific antigens
are expressed (e.g. thyroid and ovaries).4. The immune landscape of low mutation
burden tumours
As discussed, neo-antigens constitute attractive targets for
immunotherapy and clinical responses with checkpoint block-
ers have been correlated to the mutation burden of tumours
[16,62]. Cancers with 10 mutations/Mb or more have been pro-
posed as susceptible for checkpoint blockade, indicating the
importance of neo-antigen presence for a potent immune
response [116]. However, not all patients with high mutation
burden tumours benefit from these therapies, and the precise
determinants of response are undefined at the moment.
Furthermore, the division between tumours with high, moder-
ate and low mutation burden is somewhat arbitrary. In theory,
tumours with low/moderate mutation burden that present
neo-antigens in complex with HLA class I could still be eligi-
ble for T-cell-mediated immunotherapy. However, several
questions remain unanswered: does the low number of
neo-antigens translate to the improbability that a neo-antigen
‘survives’ the antigen processing machinery? On the other
hand, if a small number of neo-antigens is indeed presented
by a tumour cell, is it enough to provoke an inflammatory
response that is required for tumour elimination?
Medulloblastoma, the most common brain tumour in chil-
dren, has a low mutation burden, but was found to upregulate
IDO1 expression [117]. IDO1 enhances immunosuppressive
effects leading to an increase of Tregs and dampened activity
of effector T cells [118]. Therefore, upregulation of IDO1 can
be classified as an immune escape mechanism, indicating a
role for the immune system in the control of medulloblastoma
progression. Additionally, acute myeloid leukaemia (AML)
cells are known to overexpress PD-L1 [119] and IDO1 [120],
and AML blasts can secrete arginase II in order to promoteimmune escape by suppressing T-cell proliferation and polariz-
ing monocyte differentiation towards an M2 phenotype [121].
Another tumour with low/moderate mutation burden,
Hodgkin lymphoma, is characterized by few tumour cells
and many immune cells that are attracted by the tumour-
secreted cytokines [122]. However, these tumour-infiltrating
immune cells display an immunosuppressive rather than
anti-tumourigenic phenotype [122]. Immunotherapies are reg-
ularly employed to treat this disease, including antibodies
targeting CD20, CD30 and checkpoint inhibitors targeting
PD-1 [7,61,123]. Effectiveness of the latter may reside in the
genetic overexpression of PD-L1 by the tumour cells [122].
TILs in Hodgkin lymphoma were found to express low levels
of PD-1, but the blockade of this co-inhibitory mechanism
was shown to result in an enhanced anti-tumour activity [61].
This finding underlines the existence of a T-cell-mediated
anti-tumour response, which might be circumvented by
the tumour through PD-L1 expression. Nevertheless, the
immune evasive mechanisms observed in AML and Hodgkin
lymphoma are probably closely connected to the function of
their precursor cells and the persistent interaction of these path-
ologies with the immune system. A last example of a tumour
type with low/moderate mutation burden that has potential
for treament with immunotherapeutic strategies is renal cell
carcinoma (RCC). Sensitivity to immunotherapeutic interven-
tion in this tumour type was already known from the clinical
responses of some RCC patients to IL-2 treatment [124].
Recently, patient overall survival was shown to increase from
19.6 to 25 months with anti-PD-1 therapy compared to stan-
dard care with the mTOR inhibitor everolimus [125]. The
underlying mechanisms making this tumour susceptible
for immunotherapeutics are not understood yet, but the
composition of the tumour microenvironment might play an
important role. High lymphocyte infiltration was found to
correlate with high risk for disease progression, which is a
paradox characteristic of RCC. This might relate to the
exhausted phenotype of infiltrating lymphocytes which con-
tributes to an immunosuppressive microenvironment [126].
Furthermore, neo-antigen depletion due to immune selection
was demonstrated to occur in RCC and a positive correlation
was observed between mutations in the antigen-presenting
machinery and cytotoxic activity by immune cells, suggesting
the presence of ongoing anti-tumour immune reactions [67].
Finally, RCC was found to have the highest number of frame-
shift mutations out of 19 different cancer types, which might
explain the immunogenicity observed in these tumours despite
their moderate total mutation burden [49]. These examples of
tumours with low mutation burden presenting susceptibility
to immunotherapeutic strategies indicate the existence of auto-
logous tumour-specific T cells with the potential to recognize
(neo-) antigens, even when present in small numbers.5. Immunotherapies for tumours with low
mutation burden
Previous works by Tran et al. [82,127] support the idea that
most tumours present neo-antigens and that these can be tar-
geted by the immune system, e.g. gastrointestinal cancers
with low and moderate mutation burden including a cholan-
giocarcinoma patient with only 26 non-synonymous
mutations. Therefore, the clinical applicability of neo-antigen-
targeted ACT or peptide-based vaccination strategies for low
hot tumour cold tumour






Figure 1. (Immuno) therapeutic strategies in tumours with ‘hot’ and ‘cold’ immune microenvironments. Checkpoint blockade therapies are mostly applicable to ‘hot’
tumours which present an inflammatory profile as a consequence of their high mutation burden. We propose that ‘cold’ tumours might be sensitized to checkpoint





mutation burden tumours should be explored. The detection
rate of autologous T-cell reactivity to neo-antigens is often
described to be approximately 1% of the non-synonymous
mutations that are transcribed in a tumour [83,127,128]. Cur-
rently, NGS is regularly used to determine neo-antigen
presence, but improvements in capture methods for targeted
panels (e.g. exome) and mutation detection algorithms might
enhance the initial pool of targetable mutations in tumours
with low mutation burden. For these, the use of in silico predic-
tion models for antigen processing and HLA binding affinity
might not be necessary for a first T-cell reactivity screening
using long peptides, because the number of mutations is low
and all neo-antigens can be tested for their ability to induce
T-cell activation. However, to directly investigate T-cell
reactivity against short peptides, in silico tools are still required.
Immunotherapies have a high synergistic potential with
standard chemo- and radiotherapies as these are known to
induce immunogenic cell death [129,130]. This synergy might
be especially valuable for tumours with low mutation
burden which do not respond to immunotherapy alone, and
which could benefit from the transformation of a ‘cold’
immune microenvironment into a ‘hot’ microenvironment
with an inflammatory profile (figure 1) [131,132]. The rationale
of classical chemotherapy and radiotherapy encompasses the
targeting of fast-dividing tissues by impairing mitosis and
inducing DNA damage. This leads to the release of tumour
antigens and damage-associated molecular patterns which
activate APCs [133]. Macrophages are attracted to consume
the damaged tumour cells, which further enhances the anti-
tumour response of T cells upon presentation of the tumour
antigens [134]. In addition, radiotherapy leads to the release
of nuclear DNA in the cytoplasm, activating the stimulator ofinterferon genes (STING) pathway, which is a direct link
between the innate immune system and DNA damage
[135,136]. Furthermore, the tumour microenvironment is dis-
rupted by chemoradiation, thereby disturbing the immune
suppressive milieu in tumours. This includes increased antigen
presentation and expression of co-stimulatory molecules as
well as inhibition of regulatory T-cell and myeloid-derived
suppressor cell function [129,137–139]. In melanoma patients,
an improved clinical response rate was observed upon treat-
ment with a combination of anti-CTLA-4/PD-1 with
radiotherapy, compared to treatment without radiation [130].
Moreover, combined radiotherapy with anti-CTLA-4 treat-
ment induced abscopal effects (shrinkage of tumour lesions
outside of the target region of radiotherapy), in this case con-
sisting of complete regression of metastases at different sites
[140]. Similarly, abscopal effects were observed in a treat-
ment-refractory metastatic lung adenocarcinoma patient after
therapy with radiotherapy and ipilimumab [141]. Tumours
treated pre-surgically with neo-adjuvant therapy might be par-
ticularly interesting for the investigation of the synergistic
effect of chemoradiation and immunotherapy in cancers with
low mutation burden. Among these, rectal cancers and oeso-
phageal tumours are excellent candidates for clinical trials
aiming at reducing mortality and treatment-related morbidity.
Another avenue that may lead to the sensitization of
additional tumours to immunotherapeutic intervention is epi-
genetic modulation of cancer cells [142]. Epigenetic regulation
is fundamental for gene expression and, consequently, for
neo-antigen availability. Furthermore, in order to evade the
immune system, tumours might acquire epigenetic footprints
that change the expression of immunomodulatory genes. For




6to neo-antigens, can be suppressed in tumour cells due to
epigenetic changes [143,144]. Such observations are strongly
supportive of adopting epigenetic modifiers to restore or
improve immunogenicity of some cancers [145]. More specifi-
cally, epigenetic modifiers have been shown to increase
CD8þ T-cell infiltration in ovarian cancer and the immunogeni-
city of colorectal cancer cells was increased upon treatment
with DNA-demethylating agents [146,147]. Epigenetic drugs
could thus tackle the heterogenic expression of, among
others, HLA molecules and neo-antigens, thereby enhancing
anti-tumour immunity.
Another obstacle to employing immunotherapies for the
treatment of tumours with low mutation burden relates to
the fact that they are usually poorly infiltrated by immune
cells. The initiation of an adaptive anti-tumour immune
response probably relies on a robust inflammatory trigger
that is absent in poorly immunogenic tumours. On the other
hand, such inflammatory threshold in tumours with high
mutation burden is most likely reached due to the abundance
of mutated antigens. A strategy to artificially induce an inflam-
matory response that complements immunotherapeutic
approaches is oncolytic virotherapy (figure 1). Talimogene
laherparepvec, a genetically engineered herpes virus, replicates
specifically in cancer cells and induces tumour cell death [148].
It was also shown to induce the expression of GM-CSF in
tumours, which attracts dendritic cells that take up tumour
antigens after cancer cell death. A phase Ib clinical trial
obtained objective response rates (62%) and complete response
rates (33%) in advanced melanoma patients, which were
treated with a talimogene laherparepvec vaccination combined
with pembroluzimab (anti-PD-1 blocker) [149]. The vaccination
treatment was shown to induce infiltration of T cells that often
expressed PD-1, especially in otherwise non-infiltrated ‘cold’tumours, explaining the patients’ sensitivity to PD-1 blockade.
While such combination therapies were mainly performed in
immunogenic tumours, their success and rationale supports
the investigation of their applicability in tumours with low
mutation burden.6. Concluding remarks
Immunotherapy, particularly checkpoint blockade, can induce
robust and durable anti-tumour responses in a significant pro-
portion of patients, predominantly when applied for the
treatment of cancers with high mutation burden. Until today,
the applicability of these treatments for other cancer types is
very limited. During the last decade, different groups have
demonstrated the possibility of identifying neo-antigen-tar-
geted immune cell repsonses in tumours with intermediate/
low mutation burden. Recent work in our laboratory confirms
that neo-antigen-reactive T cells are present in low mutation
burden, mismatch repair-proficient colorectal carcinomas
(van den Bulk et al. 2018, unpublished data). These findings
underscore the relevance of developing neo-antigen targeting
immunotherapies for low mutation burden tumours by
tuning anti-tumour inflammatory responses. ‘Cold’, poorly
immunogenic, tumours will require rationale-based interven-
tions that make use of combinatorial therapies, including
radio/chemotherapy or oncolytic viruses, to switch cancer
immune microenvironments to a ‘hot’ state.
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